{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Liposarcoma",
    "query": {
      "condition": "Metastatic Liposarcoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 52,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Liposarcoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:11:03.685Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00132704",
      "title": "An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Neoplasms",
        "Colorectal Neoplasms",
        "Melanoma",
        "Small Cell Lung Cancer",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Ionizing radiation (IR) therapy",
          "type": "RADIATION"
        },
        {
          "name": "Ionizing radiation (IR)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2004-08",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132704"
    },
    {
      "nct_id": "NCT05836571",
      "title": "Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Extraskeletal Myxoid Chondrosarcoma",
        "Locally Advanced Leiomyosarcoma",
        "Locally Advanced Liposarcoma",
        "Locally Advanced Undifferentiated Pleomorphic Sarcoma",
        "Locally Advanced Unresectable Soft Tissue Sarcoma",
        "Metastatic Soft Tissue Sarcoma",
        "Metastatic Undifferentiated Pleomorphic Sarcoma",
        "Unresectable Leiomyosarcoma",
        "Unresectable Liposarcoma",
        "Unresectable Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute LAO",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2023-10-25",
      "completion_date": "2026-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 26,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05836571"
    },
    {
      "nct_id": "NCT05694871",
      "title": "Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Dedifferentiated Liposarcoma",
        "Locally Advanced Dedifferentiated Liposarcoma",
        "Metastatic Dedifferentiated Liposarcoma",
        "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Unresectable Dedifferentiated Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2023-06-07",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 194,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05694871"
    },
    {
      "nct_id": "NCT02451943",
      "title": "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 509,
      "start_date": "2015-09-14",
      "completion_date": "2024-06-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 20 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451943"
    },
    {
      "nct_id": "NCT04028479",
      "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma",
        "Adenocystic Carcinoma",
        "Anal Cancer",
        "Appendix Cancer",
        "Brain Tumor",
        "Glioblastoma",
        "Astrocytoma",
        "Bile Duct Cancer",
        "Cholangiocarcinoma",
        "Bladder Cancer",
        "Bone Cancer",
        "Synovial Sarcoma",
        "Chondrosarcoma",
        "Liposarcoma",
        "Sarcoma, Kaposi",
        "Sarcoma,Soft Tissue",
        "Sarcoma",
        "Osteosarcoma",
        "CNS Cancer",
        "Brain Stem Neoplasms",
        "Breast Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Rectal Cancer",
        "Colon Cancer",
        "Esophageal Cancer",
        "Esophagus Cancer",
        "Cancer of Colon",
        "Pancreatic Cancer",
        "Cancer of Pancreas",
        "Testis Cancer",
        "Testicular Cancer",
        "Ureter Cancer",
        "Renal Cell Carcinoma",
        "Kidney Cancer",
        "Gestational Trophoblastic Tumor",
        "Head and Neck Neoplasms",
        "Parotid Tumor",
        "Larynx Cancer",
        "Tongue Cancer",
        "Pharynx Cancer",
        "Salivary Gland Cancer",
        "Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Multiple Myeloma",
        "Non Hodgkin Lymphoma",
        "Carcinoid Tumor",
        "Lung Cancer",
        "Neuroendocrine Tumors",
        "Mesothelioma",
        "Thyroid Cancer",
        "Parathyroid Neoplasms",
        "Adrenal Cancer",
        "Small Bowel Cancer",
        "Stomach Cancer",
        "Liver Cancer",
        "Hepatic Cancer",
        "Melanoma",
        "Skin Cancer",
        "Unknown Primary Tumors",
        "Uterine Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Vaginal Cancer",
        "Penile Cancer",
        "Vulvar Cancer",
        "Waldenstrom Macroglobulinemia",
        "Cancer, Advanced",
        "Thymus Cancer",
        "Nasopharyngeal Carcinoma",
        "Multiple Endocrine Neoplasia",
        "Pheochromocytoma",
        "Small Cell Carcinoma",
        "Pulmonary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biomarker Testing (L)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Systemic Treatment (T)",
          "type": "DRUG"
        },
        {
          "name": "Patient Reported Outcomes (P)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Taproot Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2021-05-05",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 2,
      "location_summary": "Idaho Falls, Idaho • Laredo, Texas",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Laredo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04028479"
    },
    {
      "nct_id": "NCT02357810",
      "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Liposarcoma",
        "Metastatic Liposarcoma",
        "Metastatic Osteosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Liposarcoma",
        "Recurrent Osteosarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Oral Topotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2015-03-21",
      "completion_date": "2021-10-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Forest",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357810"
    },
    {
      "nct_id": "NCT06703346",
      "title": "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Letetresgene autoleucel (Lete-Cel (GSK3377794))",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "USWM CT, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2019-12-31",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 24,
      "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06703346"
    },
    {
      "nct_id": "NCT04906876",
      "title": "A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Soft Tissue Sarcoma",
        "Metastatic Sarcoma",
        "Undifferentiated Pleomorphic Sarcoma",
        "Myxofibrosarcoma",
        "Leiomyosarcoma",
        "Liposarcoma",
        "Angiosarcoma",
        "Synovial Sarcoma",
        "Rhabdomyosarcoma",
        "Spindle Cell Sarcoma",
        "High Grade Sarcoma",
        "Bone Sarcoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "9-ING-41",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-09",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2021-07-28",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04906876"
    },
    {
      "nct_id": "NCT04242238",
      "title": "Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Advanced Sarcoma",
        "High Grade Sarcoma",
        "Leiomyosarcoma",
        "Undifferentiated Pleomorphic Sarcoma",
        "Myxofibrosarcoma",
        "Dedifferentiated Liposarcoma"
      ],
      "interventions": [
        {
          "name": "DCC-3014",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-01-22",
      "completion_date": "2025-08-26",
      "has_results": false,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04242238"
    },
    {
      "nct_id": "NCT00346164",
      "title": "Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Alveolar Soft-part Sarcoma",
        "Adult Angiosarcoma",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Fibrous Histiocytoma",
        "Adult Malignant Hemangiopericytoma",
        "Adult Malignant Mesenchymoma",
        "Adult Neurofibrosarcoma",
        "Adult Synovial Sarcoma",
        "Childhood Alveolar Soft-part Sarcoma",
        "Childhood Angiosarcoma",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Mesenchymoma",
        "Childhood Neurofibrosarcoma",
        "Childhood Synovial Sarcoma",
        "Dermatofibrosarcoma Protuberans",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Nonmetastatic Childhood Soft Tissue Sarcoma",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "clinical observation",
          "type": "OTHER"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 588,
      "start_date": "2007-02-05",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-05-22T02:11:03.685Z",
      "location_count": 165,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346164"
    }
  ]
}